Needham maintains Rhythm Pharmaceuticals at Buy, lowers price target to $114 from $130

What happened

Needham kept its Buy rating on Rhythm Pharmaceuticals but cut its price target to $114 from $130, a 12.3% decrease. The new target implies 22.0% upside from the November 2 closing price of $93.44.

Confirmed

Global impact / market context

The lower target signals that Needham sees less potential value than before, even while retaining its Buy rating. If investors follow the revised view, their expectations could shift, potentially affecting demand for the shares; the article does not report any resulting market move.

Analyst inference

The article lists recent analyst targets from $130 to $159, while Needham’s new $114 target is below that range. These are analyst estimates, not guaranteed outcomes, and the differing views show uncertainty about Rhythm Pharmaceuticals’ future share value.

Confirmed

What to watch

1. Whether other analysts change their ratings or targets, since further cuts could reinforce a more cautious view of the company’s expected share value. Analyst inference
2. Whether Rhythm Pharmaceuticals reports company developments that explain analysts’ estimates; the supplied article provides no business results or reasons for Needham’s target cut. Analyst inference
3. How the share price compares with Needham’s $114 target and the November 2 close of $93.44; the article gives no later trading data. Analyst inference

Evidence

• Original source link unavailable